Supplementary Material 6: Sensitivity analyses.

Figure 1: Prevalence of MG infection among PrEP users, estimated with Freeman-Tukey double arcsine as the transformation method for prevalence estimates.




Figure 2: Prevalence of macrolide-resistant MG infection among PrEP users, estimated with Freeman-Tukey double arcsine as the transformation method for prevalence estimates.

M	acrolide resista	int				
Study	MG+	n			Prevalen	ce 95%CI
Point prevalence					Ĩ	
Couldwell et al., 2018	26	33			78.79	[61.09; 91.02]
McIver et al., 2019	12	14			85.71	[57.19; 98.22]
Read et al., 2019	16	16		_	100.00	[79.41; 100.00]
Random effects model		63			90.01	[71.65; 99.89]
Prediction interval					-	[0.00; 100.00]
Heterogeneity: $I^2 = 67\%$						
Period prevalence (6 mon	the)					
Berçot et al., 2021	16	23			69.57	[47.08; 86.79]
				_		[]
Period prevalence (9 mon	ths)					
Guiraud et al., 2021	12	16		-	75.00	[47.62; 92.73]
Period prevalence (24 mo		2.2		_		
Ducours et al., 2019	21	28			75.00	[55.13; 89.31]
			0 20	10 60 90	100	
			0 20	40 60 80	100	